Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials

被引:19
作者
Aminesmaeili, Masoumeh [1 ,2 ]
Farokhnia, Mehdi [1 ,3 ,4 ]
Susukida, Ryoko [1 ]
Leggio, Lorenzo [3 ,4 ,5 ,6 ,7 ]
Johnson, Renee M. [1 ]
Crum, Rosa M. [1 ,8 ,9 ]
Mojtabai, Ramin [1 ,9 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA
[2] Univ Tehran Med Sci, Iranian Natl Ctr Addict Studies INCAS, Tehran, Iran
[3] Natl Inst Drug Abuse Intramural Res Program, Translat Addict Med Branch, Clin Psychoneuro endocrinol & Neuropsycho pharmac, Baltimore, MD USA
[4] NIAAA, NIH, Div Intramural Clin & Biol Res, Baltimore, MD USA
[5] NIDAI, NIH, Medicat Dev Program, Baltimore, MD USA
[6] Brown Univ, Ctr Alcohol & Addict Studies, Dept Behav & Social Sci, Providence, RI USA
[7] Johns Hopkins Univ, Sch Med, Dept Med, Div Addict Med, Baltimore, MD USA
[8] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[9] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Sch Med, Baltimore, MD USA
关键词
cocaine use disorder; harm reduction; methamphetamine use disorder; non-abstinence outcomes; secondary data analysis; Stimulants; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; DOUBLE-BLIND; ALCOHOL DEPENDENCE; COCAINE USE; ABSTINENCE; DEPRESSION; METAANALYSIS; ONDANSETRON; MODAFINIL;
D O I
10.1111/add.16409
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background and aimsTotal abstinence has historically been the goal of treatment for substance use disorders; however, there is a growing recognition of the health benefits associated with reduced use as a harm reduction measure in stimulant use disorders treatment. We aimed to assess the validity of reduced stimulant use as an outcome measure in randomized controlled trials (RCTs) of pharmacological interventions for stimulant use disorder.DesignWe conducted a secondary analysis of a pooled dataset of 13 RCTs.Setting and participantsParticipants were individuals seeking treatment for cocaine or methamphetamine use disorders (N = 2062) in a wide range of treatment facilities in the United States.MeasurementsWe validated reduced stimulant use against a set of clinical indicators drawn from harmonized measurements, including severity of problems caused by drug use, comorbid depression, global severity of substance use and improvement, severity of drug-seeking behavior, craving and high-risk behaviors, all assessed at the end of the trial, as well as follow-up urine toxicology. A series of mixed effect regression models was conducted to validate reduction in frequency of use against no reduction in use and abstinence.FindingsMore participants reduced frequency of primary drug use than achieved abstinence (18.0% vs. 14.2%, respectively). Reduced use was significantly associated with decreases in craving for the primary drug [60.1%, 95% confidence interval (CI) = 54.3%-64.7%], drug seeking behaviors (41.0%, 95% CI = 36.6%-45.7%), depression severity (39.9%, 95% CI = 30.9%-48.3%), as well as multiple measures of global improvement in psychosocial functioning and severity of drug-related problems, albeit less strongly so than abstinence. Moreover, reduced use was associated with sustained clinical benefit at follow-up, as confirmed by negative urine tests (adjusted odds ratio compared with those with no reduction in use: 0.50, 95% CI = 0.35-0.71).ConclusionReduced frequency of stimulant use appears to be associated with meaningful improvement in various clinical indicators of recovery. Assessment of reduced use, in addition to abstinence, could broaden the scope of outcomes measured in randomized controlled trials of stimulant use disorders and facilitate the development of more diverse treatment approaches.
引用
收藏
页码:833 / 843
页数:11
相关论文
共 59 条
  • [1] Individual participant data meta-analyses should not ignore clustering
    Abo-Zaid, Ghada
    Guo, Boliang
    Deeks, Jonathan J.
    Debray, Thomas P. A.
    Steyerberg, Ewout W.
    Moons, Karel G. M.
    Riley, Richard David
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2013, 66 (08) : 865 - 873
  • [2] Adjust for Multiple Comparisons? It's Not That Simple
    Althouse, Andrew D.
    [J]. ANNALS OF THORACIC SURGERY, 2016, 101 (05) : 1644 - 1645
  • [3] Patterns of reduced use and abstinence in multi-site randomized controlled trials of pharmacotherapies for cocaine and methamphetamine use disorders
    Amin-Esmaeili, Masoumeh
    Susukida, Ryoko
    Johnson, Renee M.
    Farokhnia, Mehdi
    Crum, Rosa M.
    Thrul, Johannes
    Mojtabai, Ramin
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2021, 226
  • [4] Bupropion for the treatment of methamphetamine dependence in non-daily users: A randomized, double-blind, placebo-controlled trial
    Anderson, Ann L.
    Li, Shou-Hua
    Markova, Denka
    Holmes, Tyson H.
    Chiang, Nora
    Kahn, Roberta
    Campbell, Jan
    Dickerson, Daniel L.
    Galloway, Gantt P.
    Haning, William
    Roache, John D.
    Stock, Christopher
    Elkashef, Ahmed M.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2015, 150 : 170 - 174
  • [5] Modafinil for the treatment of methamphetamine dependence
    Anderson, Ann L.
    Li, Shou-Hua
    Biswas, Kousick
    McSherry, Frances
    Holmes, Tyson
    Iturriaga, Erin
    Kahn, Roberta
    Chiang, Nora
    Beresford, Thomas
    Campbell, Jan
    Haning, William
    Mawhinney, Joseph
    McCann, Michael
    Rawson, Richard
    Stock, Christopher
    Weis, Dennis
    Yu, Elmer
    Elkashef, Ahmed M.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2012, 120 (1-3) : 135 - 141
  • [6] Modafinil for the treatment of cocaine dependence
    Anderson, Ann L.
    Reid, Malcolm S.
    Li, Shou-Hua
    Holmes, Tyson
    Shemanski, Lynn
    Slee, April
    Smith, Edwina V.
    Kahn, Roberta
    Chiang, Nora
    Vocci, Frank
    Ciraulo, Domenic
    Dackis, Charles
    Roache, John D.
    Salloum, Ihsan M.
    Somoza, Eugene
    Urschel, Harold C., III
    Elkashef, Ahmed M.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2009, 104 (1-2) : 133 - 139
  • [7] Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder
    Brezing, Christina A.
    Choi, C. Jean
    Pavlicova, Martina
    Brooks, Daniel
    Mahony, Amy L.
    Mariani, John J.
    Levin, Frances R.
    [J]. AMERICAN JOURNAL ON ADDICTIONS, 2018, 27 (02) : 101 - 107
  • [8] Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ
    Burke, Danielle L.
    Ensor, Joie
    Riley, Richard D.
    [J]. STATISTICS IN MEDICINE, 2017, 36 (05) : 855 - 875
  • [9] The Montgomery Asberg and the Hamilton ratings of depression: A comparison of measures
    Carmody, Thomas J.
    Rush, A. John
    Bernstein, Ira
    Warden, Diane
    Brannan, Stephen
    Burnham, Daniel
    Woo, Ada
    Trivedi, Madhukar H.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 (08) : 601 - 611
  • [10] THE RELIABILITY AND VALIDITY OF A SCALE TO MEASURE HIV RISK-TAKING BEHAVIOR AMONG INTRAVENOUS-DRUG-USERS
    DARKE, S
    HALL, W
    HEATHER, N
    WARD, J
    WODAK, A
    [J]. AIDS, 1991, 5 (02) : 181 - 185